3rd Quarter - Amendment
CSL BEHRING LLC for CSL BEHRING LLC
Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 1, 2014 | $170,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Oct 1, 2014 | $170,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN R. BULLARD | Sr. Manager, Federal Government Affairs |
| PATRICK COLLINS | Director, Healthcare Policy and External Affairs |
| DENNIS JACKMAN | Sr. Vice President, Healthcare Policy and External Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.